NAS:VCYT (USA)
Business Description
Veracyte Inc
NAICS : 325412
SIC : 2834
6000 Shoreline Court, Suite 300, South San Francisco, CA, USA, 94080
Compare
Compare
Traded in other countries / regions
12V.Germany
•
VCYT.USA
Description
Veracyte Inc is a genomic diagnostics company. It provides genomic diagnostic products and services to improve patient care against diseases such as thyroid cancer, lung cancer, and idiopathic pulmonary fibrosis. The firm's product portfolio consists of products such as Afirma analysis, Percepta, Envisia, and others. The company derives its revenues from the Sale of Afirma analysis product.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 9.32 | |||||
| Equity-to-Asset | 0.93 | |||||
| Debt-to-Equity | 0.02 | |||||
| Debt-to-EBITDA | -0.7 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | 14.2 | |||||
| Beneish M-Score | -2.24 | |||||
| WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 9.2 | |||||
| 3-Year EBITDA Growth Rate | -25.4 | |||||
| 3-Year EPS without NRI Growth Rate | -21.4 | |||||
| 3-Year FCF Growth Rate | -9.4 | |||||
| 3-Year Book Growth Rate | 99.1 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 52.6 | |||||
| 9-Day RSI | 55.13 | |||||
| 14-Day RSI | 56.67 | |||||
| 6-1 Month Momentum % | -14.95 | |||||
| 12-1 Month Momentum % | -45.5 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.96 | |||||
| Quick Ratio | 3.71 | |||||
| Cash Ratio | 2.76 | |||||
| Days Inventory | 42.81 | |||||
| Days Sales Outstanding | 53.47 | |||||
| Days Payable | 41.98 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -20.3 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 65.24 | |||||
| Operating Margin % | -19.24 | |||||
| Net Margin % | -18.13 | |||||
| ROE % | -4.57 | |||||
| ROA % | -4.25 | |||||
| ROIC % | -5.32 | |||||
| ROC (Joel Greenblatt) % | -111.95 | |||||
| ROCE % | -4.65 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 6.38 | |||||
| PB Ratio | 1.62 | |||||
| Price-to-Tangible-Book | 9.11 | |||||
| EV-to-EBIT | -30.71 | |||||
| EV-to-EBITDA | -60.72 | |||||
| EV-to-Revenue | 5.93 | |||||
| EV-to-FCF | -181.05 | |||||
| Price-to-Projected-FCF | 2.74 | |||||
| Price-to-Net-Current-Asset-Value | 11.12 | |||||
| Price-to-Net-Cash | 20.62 | |||||
| Earnings Yield (Greenblatt) % | -3.27 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Gurus Latest Trades with NAS:VCYT
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 268.353 | ||
| EPS (TTM) ($) | -0.68 | ||
| Beta | 1.39 | ||
| Volatility % | 57.19 | ||
| 14-Day RSI | 56.67 | ||
| 14-Day ATR ($) | 1.874897 | ||
| 20-Day SMA ($) | 26.0525 | ||
| 12-1 Month Momentum % | -45.5 | ||
| 52-Week Range ($) | 14.85 - 54.13 | ||
| Shares Outstanding (Mil) | 71.58 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Veracyte Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||